HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

The extent and importance of autoimmune mechanisms in myelodysplastic syndrome (MDS) and the role of immunosuppression in the treatment of this disease are not well defined. We report overrepresentation of HLA-DR2 and its serologic split HLA-DR15 in both MDS and aplastic anemia (AA). Four clinically and ethnically defined patient groups were analyzed. The HLA-DR15 antigen frequencies among North American white MDS patients (n = 72) and AA patients (n = 59), who received immunosuppressive treatment at the National Institutes of Health (NIH), were 36% and 42%, respectively. These antigen frequencies were significantly higher than that of the control population of 240 North American white NIH blood donors typed for HLA antigens by the same molecular technique (HLA-DR15, 21.3%, P =.01 for MDS, P <.001 for AA). Among North American white patients reported in the International Bone Marrow Transplant Registry (IBMTR), 30% of 341 MDS patients and 33% of 364 AA patients were positive for HLA-DR2. These antigen frequencies were higher than those reported for the general North American white population (HLA-DR2, 25.3%, P =.089 for MDS, P =.01 for AA). The DR15 and DR2 frequencies were significantly increased in MDS refractory anemia (RA) (P =.036 and P =.01, respectively) but not MDS refractory anemia with excess blasts. In the NIH MDS patients, HLA-DR15 was significantly associated with a clinically relevant response to antithymocyte globulin (ATG) or cyclosporine immunosuppression (multivariate analysis, P =.008). In MDS with RA, DR15 may be useful as a guide to pathophysiology, prognosis, and treatment.

[1]  D. Follmann,et al.  Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. , 2001, Blood.

[2]  N. Young,et al.  Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features , 2001, British journal of haematology.

[3]  A. Raza,et al.  Anti‐TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes , 2000, Microscopy research and technique.

[4]  M. Okada,et al.  Good response to cyclosporine therapy in patients with myelodysplastic syndrromes having the HLA-DRB1*1501 allele , 2000, Leukemia.

[5]  Y. Saunthararajah,et al.  Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? , 2000, Seminars in hematology.

[6]  A. Raza,et al.  Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. , 1999, Anticancer research.

[7]  A. Barrett,et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.

[8]  J. Čermák,et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.

[9]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[10]  N. Young,et al.  The pathophysiology of acquired aplastic anemia. , 1997, The New England journal of medicine.

[11]  J. G. van den Tweel,et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.

[12]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[13]  H. Mizoguchi,et al.  Response to immunosuppressive therapy and an HLA‐DRB1 allele in patients with aplastic anaemia: HLA‐DRB1*1501 does not predict response to antithymocyte globulin , 1996, British journal of haematology.

[14]  N. Young,et al.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. , 1995, Blood.

[15]  R. Peces,et al.  Influence of HLA-DR phenotype on tumor necrosis factor-alpha production in renal-transplant recipients. , 1995, Nephron.

[16]  H. Mizoguchi,et al.  Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. , 1994, Blood.

[17]  M. Barnardo,et al.  Improvements in HLA-C typing using sequence-specific primers (PCR-SSP) including definition of HLA-Cw9 and Cw10 and a new allele HLA-"Cw7/8v". , 1994, Tissue antigens.

[18]  M. Dhodapkar,et al.  Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? , 1994, Blood.

[19]  S. Nimer,et al.  An Increased HLA DR2 Frequency Is Seen in Aplastic Anemia Patients , 1994 .

[20]  M. Bunce,et al.  Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. , 1994, Tissue antigens.

[21]  S. Nimer,et al.  An increased HLA DR2 frequency is seen in aplastic anemia patients. , 1994, Blood.

[22]  S. Asano,et al.  Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. , 1993, International journal of hematology.

[23]  K. Yoshinaga,et al.  T cell‐mediated inhibition of erythropoiesis in myelodysplastic syndromes , 1992, American journal of hematology.

[24]  J. Storek.  Chronic neutrophilic leukemia: Case report documenting the absence of bcr‐abl rearrangement , 1992, American journal of hematology.

[25]  M. Matsuda,et al.  Increased production of tumor necrosis factor‐α by peripheral blood mononuclear cells in the patients with aplastic anemia , 1991, American journal of hematology.

[26]  J. Smith,et al.  The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. , 1991, Leukemia research.

[27]  N. Morling,et al.  Association between HLA‐DR2 and Production of Tumour Necrosis Factor α and Interleukin 1 by Mononuclear Cells Activated by Lipopolysaccharide , 1988, Scandinavian journal of immunology.

[28]  H. Uchino,et al.  Refractory myelodysplastic anaemias with hypocellular bone marrow. , 1988, Journal of clinical pathology.

[29]  A. Gratwohl,et al.  ANTILYMPHOCYTE GLOBULIN FOR MYELODYSPLASTIC SYNDROME? , 1988, British journal of haematology.

[30]  A. Gratwohl,et al.  Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents , 1986, British journal of haematology.

[31]  P. McCullagh.  Analysis of Ordinal Categorical Data , 1985 .

[32]  G. Tricot,et al.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.